Innovent Biologics Inc ADR IVBIY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IVBIY is a good fit for your portfolio.
News
-
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
-
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
-
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
-
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
-
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
-
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
-
Innovent Announces 2023 Annual Results and Business Updates
-
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
Trading Information
- Previous Close Price
- $18.66
- Day Range
- $19.48–19.48
- 52-Week Range
- $13.00–24.14
- Bid/Ask
- $12.46 / $50.00
- Market Cap
- $7.84 Bil
- Volume/Avg
- 1,103 / 848
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 4,872
- Website
- https://www.innoventbio.com
Competitors
Valuation
|
Metric
|
IVBIY
|
01099
|
02269
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 6.39 | 15.13 |
Price/Book Value | 5.04 | 0.74 | 1.43 |
Price/Sales | 8.66 | 0.09 | 3.22 |
Price/Cash Flow | — | 3.10 | 10.26 |
Price/Earnings
IVBIY
01099
02269
Financial Strength
|
Metric
|
IVBIY
|
01099
|
02269
|
|---|---|---|---|
Quick Ratio | 2.59 | 1.05 | 2.35 |
Current Ratio | 3.00 | 1.39 | 2.78 |
Interest Coverage | −15.20 | 7.35 | 25.95 |
Quick Ratio
IVBIY
01099
02269
Profitability
|
Metric
|
IVBIY
|
01099
|
02269
|
|---|---|---|---|
Return on Assets (Normalized) | −2.75% | 4.43% | 8.91% |
Return on Equity (Normalized) | −5.12% | 24.34% | 13.28% |
Return on Invested Capital (Normalized) | −5.63% | 9.74% | 10.45% |
Return on Assets
IVBIY
01099
02269
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lgnxpzfxd | Wlsx | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Prjnybs | Qpyhrb | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vjhgjgb | Ztydcfv | $103.7 Bil | |
MRNA
| Moderna Inc | Mcbzwtqg | Hngc | $47.9 Bil | |
ARGX
| argenx SE ADR | Wzvcvvzq | Prcv | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Jnsvylwy | Gbpb | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gqtyhkgqg | Pjmjt | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Txmtfrst | Vxhbc | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wnqplqqjq | Dbjnryx | $12.8 Bil | |
INCY
| Incyte Corp | Dkfjggwpy | Jmwqx | $12.1 Bil |